Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
J Pharmacol Exp Ther ; 291(2): 739-48, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10525095

ABSTRACT

Phosphorylation of tyrosine residues on the epidermal growth factor (EGF) receptor (EGFr) is an important early event in signal transduction, leading to cell replication for major human carcinomas. CP-358,774 is a potent and selective inhibitor of the EGFr tyrosine kinase and produces selective inhibition of EGF-mediated tumor cell mitogenesis. To assess the pharmacodynamic aspects of EGFr inhibition, we devised an ex vivo enzyme-linked immunosorbent assay for quantification of EGFr-specific tyrosine phosphorylation in human tumor tissue specimens obtained from xenografts growing s.c. in athymic mice. When coupled with pharmacokinetic analyses, this measurement can be used to describe the extent and duration of kinase inhibition in vivo. CP-358,774 is an effective, orally active inhibitor of EGFr-specific tyrosine phosphorylation (ED(50) = 10 mg/kg, single dose). It has a significant duration of action, producing, on average, a 70% reduction in EGFr-associated phosphotyrosine over a 24-h period after a single 100 mg/kg dose. Inhibition of EGFr phosphotyrosine in an ex vivo assay format effectively estimates the potency and degree of inhibition of EGFr-dependent human LICR-LON-HN5 head and neck carcinoma tumor growth. Substantial growth inhibition of human tumor xenografts was achieved with p.o. doses of the compound (ED(50) = 10 mg/kg q.d. for 20 days). Combination chemotherapy with cisplatin produced a significant response above that of cisplatin alone with no detectable effects on body weight or lethal toxicity. Taken together, these observations suggest that CP-358,774 may be useful for the treatment of EGFr-driven human carcinomas.


Subject(s)
Antineoplastic Agents/pharmacology , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/physiology , Quinazolines/pharmacology , Tyrosine/metabolism , Animals , Body Weight/drug effects , Cell Division/drug effects , Cisplatin/toxicity , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Enzyme-Linked Immunosorbent Assay/methods , Erlotinib Hydrochloride , Female , Head and Neck Neoplasms/pathology , Humans , Mice , Mice, Nude , Phosphorylation , Phosphotyrosine/metabolism , Polypharmacy , Quinazolines/blood , Time Factors , Transplantation, Heterologous/physiology , Tumor Cells, Cultured
2.
J Med Chem ; 38(19): 3806-12, 1995 Sep 15.
Article in English | MEDLINE | ID: mdl-7562911

ABSTRACT

The erbB-2 oncogene encodes a transmembrane protein tyrosine kinase which plays a pivotal role in signal transduction and has been implicated when overexpressed in breast, ovarian, and gastric cancers. Naturally occurring benzoquinoid ansamycin antibiotics herbimycin A, geldanamycin (GDM), and dihydrogeldanamycin were found to potently deplete p185, the erbB-2 oncoprotein, in human breast cancer SKBR-3 cells in culture. Chemistry efforts to modify selectively the quinoid moiety of GDM afforded derivatives with greater potency in vitro and in vivo. Analogs demonstrated inhibition of p185 phosphotyrosine in cell culture and in vivo after systemic drug administration to nu/nu nude mice bearing Fisher rat embryo cells transfected with human erbB-2 (FRE/erbB-2). Specifically, dosed intraperitoneally at 100 mg/kg, 17-(allylamino)-17-demethoxygeldanamycin and other 17-amino analogs were effective at reducing p185 phosphotyrosine in subcutaneous flank FRE/erbB-2 tumors. Modifications to the 17-19-positions of the quinone ring revealed a broad structure-activity relationship in vitro.


Subject(s)
Antibiotics, Antineoplastic/chemistry , Antibiotics, Antineoplastic/pharmacology , Quinones/chemistry , Quinones/pharmacology , Receptor, ErbB-2/antagonists & inhibitors , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Antibiotics, Antineoplastic/metabolism , Benzoquinones , Breast Neoplasms/drug therapy , Dose-Response Relationship, Drug , Female , Humans , Lactams, Macrocyclic , Mice , Mice, Nude , Phosphotyrosine/metabolism , Protein-Tyrosine Kinases/antagonists & inhibitors , Quinones/metabolism , Rats , Rifabutin/analogs & derivatives , Structure-Activity Relationship , Transfection , Tumor Cells, Cultured
3.
J Med Chem ; 38(19): 3813-20, 1995 Sep 15.
Article in English | MEDLINE | ID: mdl-7562912

ABSTRACT

Overexpression of the erbB-2 oncogene has been linked to poor prognosis in breast, ovarian, and gastric cancers. Naturally occurring benzoquinoid ansamycin antibiotics herbimycin A, geldanamycin (GDM), and dihydrogeldanamycin were found to potently deplete p185, the erbB-2 oncoprotein, in human breast cancer SKBR-3 cells in culture. Chemistry efforts to modify selectively the ansa ring of GDM afforded derivatives with greater potency in vitro and in vivo. Analogs demonstrated inhibition of p185 phosphotyrosine in cell culture and in vivo after systemic drug administration to nu/nu nude mice bearing Fisher rat embryo cells transfected with human erbB-2. Functional group modification in the ansa ring was performed stereoselectively and regiospecifically without the need for protection strategies. Essential functional groups that were required for anti-erbB-2 activity were the 7-carbamate and the 2,3-double bond. Modification of the functional groups at the other positions was permitted. Structure-activity relationships are described for 1-5-, 7-9-, 11-, 15-, and 22-substituted geldanamycins.


Subject(s)
Antibiotics, Antineoplastic/chemical synthesis , Quinones/chemical synthesis , Quinones/pharmacology , Receptor, ErbB-2/antagonists & inhibitors , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Antibiotics, Antineoplastic/chemistry , Antibiotics, Antineoplastic/pharmacology , Benzoquinones , Breast Neoplasms/drug therapy , Female , Genes, erbB-2 , Humans , Lactams, Macrocyclic , Mice , Mice, Nude , Molecular Conformation , Molecular Structure , Protein-Tyrosine Kinases/antagonists & inhibitors , Quinones/chemistry , Quinones/metabolism , Rats , Receptor, ErbB-2/genetics , Structure-Activity Relationship , Transfection
5.
J Trauma ; 20(2): 123-6, 1980 Feb.
Article in English | MEDLINE | ID: mdl-6986473

ABSTRACT

We have developed a new method for coupling the hemostatic capabilities of argon laser light with the mechanical advantages of a sharpened quartz blade using fiberoptics. Using the new laser-assisted scalpel, a series of symmetrical skin excisions was done in 20- to 30-kg pigs on one side and with electrosurgery on the other. The laser scalpel was superior in its hemostatic properties (p less than 0.01) with no statistically significant difference in surgical speed. Take of split-thickness skin grafts was 90% in beds excised with either the laser or the electrosurgical device. Histologic sections showed less tissue damage with the laser-assisted scalpel than with electrocautery.


Subject(s)
Burns/surgery , Fiber Optic Technology/instrumentation , Laser Therapy , Lasers/instrumentation , Surgical Instruments/standards , Animals , Electrosurgery/instrumentation , Humans , Skin Transplantation , Swine , Transplantation, Autologous
SELECTION OF CITATIONS
SEARCH DETAIL
...